Ultragenyx Pharmaceutical RARE Intangibles (Net)
Intangibles (Net) at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's intangibles (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's intangibles (net)?
- Ultragenyx Pharmaceutical (RARE) reported intangibles (net) of $174M in Q1 2026.
- How has Ultragenyx Pharmaceutical's intangibles (net) changed year-over-year?
- Ultragenyx Pharmaceutical's intangibles (net) decreased by 1.4% year-over-year, from $176.52M to $174M.
- What is the long-term trend for Ultragenyx Pharmaceutical's intangibles (net)?
- Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's intangibles (net) has grown at a 6.1% compound annual growth rate (CAGR), from $131.11M to $176M.
- What does intangibles (net) mean?
- Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.